难治性类风湿关节炎管理的新趋势:靶向治疗与非药物干预
本文为叙述性综述,讨论难治性类风湿关节炎(D2T RA)的定义背景与管理策略。文章指出部分RA患者长期未能达到充分疾病控制,生物制剂与JAK抑制剂对传统治疗抵抗者有效,而定制化非药物疗法主要针对非炎症相关症状。
要点
- D2T RA为异质性状况,由多种潜在因素复杂交互维持。
- 生物制剂与JAK抑制剂可减轻传统治疗抵抗患者的疾病活动。
- 非药物疗法(物理治疗、心理干预等)主要针对非持续炎症相关症状。
核心结论
- D2T RA概念有助于为多程靶向药物后仍症状持续的患者提供更结构化的照护与研究框架。
- 生物制剂与JAK抑制剂对传统治疗抵抗患者可减轻疾病活动,定制化非药物疗法作为药物补充主要处理非炎症相关症状。
研究设计与样本
- 叙述性综述,检索范围未在摘要中具体报告。
主要发现
- 相当部分RA患者长期未能达到充分疾病控制。
- D2T RA为异质性状况,由多种潜在因素的复杂交互维持。
- 生物制剂与JAK抑制剂在传统治疗抵抗患者中显示减轻疾病活动的疗效。
临床怎么用
- 遵循达标治疗原则,根据特定结局调整治疗方案。
- 对多程靶向药物后仍症状持续者按D2T RA进行结构化识别与管理。
- 在药物治疗基础上联合定制化非药物疗法(物理治疗、心理干预等)以处理非炎症相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with RA often require alterations of their therapeutic regimen throughout the course of their illness, guided by specific outcomes in line with the treat-to-target principle. Importantly, a significant portion of the RA population fails to achieve sufficient disease control in the long term. Several years ago, the umbrella notion of difficult-to-treat (D2T) RA was introduced to facilitate more structured care and research efforts for patients who remain symptomatic despite having received multiple courses of targeted medications. D2T RA represents a heterogeneous condition sustained by a complex interplay of underlying factors. Biological therapies and Janus kinase inhibitors have demonstrated efficacy in alleviating disease activity in patients refractory to conventional treatments. The use of tailored non-pharmacological therapies (physiotherapy, psychological interventions, etc.) to complement pharmacotherapy chiefly addresses symptoms unrelated to ongoing inflammation. In this narrative review, we examine the current use and relevance of pharmacological and non-pharmacological approaches for D2T RA.
引用
- Nagy G, Sonomoto K, Dorgó AM, et al. Emerging trends in the management of difficult-to-treat rheumatoid arthritis: targeted treatments and non-pharmacological interventions. Rheumatology (Oxford). 2026. PMID: 42018734. doi:10.1093/rheumatology/keag217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。